Semaglutide works for most people, but not everyone responds the same way
Side Effect Profiles And GI Tolerability Differences Because oral and injectable GLP-1s use the same class of medication, their safety profile and potential side effects are very similar
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbl JD, Hansen T et al (2017) Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Similar findings were demonstrated by liraglutide, which was also found to exert endothelial protective properties in human vascular endothelial cells (hVECs) through inhibition of stimulated plasminogen activator inhibitor type-1 (PAI-1) and vascular adhesion molecule (VAM) expression
All patients reduced their insulin dose by 20% at randomization to reduce the risk of hypoglycemia